Oxymetazoline
AFRIN
What it isAlpha-1 and alpha-2 agonist causing local vasoconstriction; nasal congestion and rosacea erythema.
Why this oneThe same rapid topical vasoconstriction also makes it useful for epistaxis without systemic decongestant exposure.
What limits itContinuous nasal use beyond three days can cause severe rebound congestion and escalating spray dependence.
FDA-approved for
- nasal congestion (1964)
- rosacea erythema (topical) (2017)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Nasal congestion | Adults & children ≥6 yr (with supervision) | 2-3 sprays each nostril q10-12h PRN | 2 doses per 24 h |
Renal Undefined
Hepatic Undefined
Do not exceed 2 doses in any 24-hour period
Instructions
- Do not tilt head backward while spraying; squeeze bottle quickly and firmly
- Wipe nozzle clean after use and secure cap
- Children under 6 yr: ask a doctor
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskRebound congestion after three days
Cost, est. cash$200–$1,000/month
Generic entry2021
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.
Mechanism of action: Oxymetazoline ballicule
